Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | MIR22 host gene |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | other |
| Sample | Patient-derived glioblastoma stem-like cells (GSCs) GBMP3, GBMBG7, GBMBG5 and GBM06,neural stem cells |
| Expression Pattern | up-regulated |
| Function Description | The MIR22HG/miR-22 axis was highly expressed in glioblastoma as well as in glioma stem-like cells compared to normal neural stem cells. In glioblastoma, increased expression of MIR22HG is associated with poor prognosis. Through a number of functional studies, we show that MIR22HG silencing inhibits the Wnt/?-catenin signalling pathway through loss of miR-22-3p and -5p. This leads to attenuated cell proliferation, invasion and in vivo tumour growth. |
| Pubmed ID | 31891366 |
| Year | 2020 |
| Title | Interfering With Long Non-Coding RNA MIR22HG Processing Inhibits Glioblastoma Progression Through Suppression of Wnt/?-catenin Signalling |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |